Health ❯ Healthcare ❯ Clinical Trials ❯ Phase 3 Trials

ASCENT-03 Trial

Sacituzumab Govitecan Gains First-Line Ground in TNBC, Falls Short in Early HR+/HER2− Use

SABCS presentations underscore subtype‑specific use requiring careful treatment sequencing.

ASCENT-03 Finds Sacituzumab Govitecan Extends PFS Over Chemotherapy in First-Line PD-L1–Negative TNBC